Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.20.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
 9 Months Ended 12 Months Ended
Dec. 31, 2018
Dec. 31, 2019
Income Statement [Abstract]    
Revenue:
Operating expenses:    
General and administrative 903,913 2,245,219
Goodwill impairment 102,000
Professional fees 917,936 3,473,300
Bad debts expense 50,000
Total operating expenses 1,871,849 5,820,519
Operating loss (1,871,849) (5,820,519)
Other income (expense):    
Loss on disposal of assets (4,087)
Interest income 4
Interest expense (88,234) (382,582)
Total other expense (88,234) (386,665)
Net loss (1,960,083) (6,207,184)
Less: Net loss attributable to noncontrolling interest 101
Net loss attributable to One World Pharma, Inc. (1,959,982) (6,207,184)
Other comprehensive loss:    
Loss on foreign currency translation (4,090) (12,158)
Net other comprehensive loss $ (1,964,072) $ (6,219,342)
Weighted average number of common shares outstanding - basic and fully diluted 31,992,168 41,089,784
Net loss per share - basic and fully diluted $ (0.06) $ (0.15)